PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice.
about
The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disordersAntioxidants and Dementia Risk: Consideration through a Cerebrovascular PerspectiveHIV-1 Transactivator Protein Induces ZO-1 and Neprilysin Dysfunction in Brain Endothelial Cells via the Ras Signaling Pathway.Multifaceted Mechanisms of WY-14643 to Stabilize the Blood-Brain Barrier in a Model of Traumatic Brain InjuryChronic central nervous system expression of HIV-1 Tat leads to accelerated rarefaction of neocortical capillaries and loss of red blood cell velocity heterogeneity.New insights into immune reconstitution inflammatory syndrome of the central nervous system.Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment.HIV-1 Tat C phosphorylates VE-cadherin complex and increases human brain microvascular endothelial cell permeability.LPS Induces Occludin Dysregulation in Cerebral Microvascular Endothelial Cells via MAPK Signaling and Augmenting MMP-2 LevelsThe role of APOE in cerebrovascular dysfunctionHIV-1 Tat Regulates Occludin and Aβ Transfer Receptor Expression in Brain Endothelial Cells via Rho/ROCK Signaling PathwayPharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease.Tat is a multifunctional viral protein that modulates cellular gene expression and functions.Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation.Rosiglitazone suppresses HIV-1 Tat-induced vascular inflammation via Akt signaling.Generation of Hutat2:Fc Knockin Primary Human Monocytes Using CRISPR/Cas9.
P2860
Q26777952-BFB2E657-1C53-44C3-8985-05AF6CD14217Q28067402-0A8AE23C-674A-4306-9975-6FEE835A5D05Q33695622-1AC8B991-0618-48CE-B487-AFB753BCB6E1Q33729415-512F7E16-A934-4E20-A271-1DFCBEE35097Q34324750-FDBCBEA1-26FC-4D62-9AD4-ABB43FA8B778Q34433828-9D275B87-D0A0-441C-8CC8-5D93DB0DC081Q35078274-B839F80E-6AB9-41A1-8FA2-338091177D0CQ35194936-82C17DF3-DEA0-4642-B789-6F127AEE447AQ35935524-F8D1066D-932B-48BB-B519-157987ABA5D8Q36813704-B312C2E8-141B-41BC-8D44-B7BA0896E269Q37176830-F9BD13A7-1C68-40CE-90BC-09906A3FC497Q38672178-86D21DE7-AC98-4810-85DE-D0659F5A7923Q39130522-037F2BC6-13FC-4A2D-AC24-F0C420DE9D3DQ40050469-DE4D3FD6-9021-41AC-ABD9-FCAED67EC74CQ41690085-47E91A18-D421-4D2C-8FA1-9002A124D67FQ55279894-60099D31-E02D-4411-AC3F-2F2B78CDEB81
P2860
PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PPAR agonist-mediated protecti ...... anced in MMP-9-deficient mice.
@en
PPAR agonist-mediated protecti ...... anced in MMP-9-deficient mice.
@nl
type
label
PPAR agonist-mediated protecti ...... anced in MMP-9-deficient mice.
@en
PPAR agonist-mediated protecti ...... anced in MMP-9-deficient mice.
@nl
prefLabel
PPAR agonist-mediated protecti ...... anced in MMP-9-deficient mice.
@en
PPAR agonist-mediated protecti ...... anced in MMP-9-deficient mice.
@nl
P2093
P2860
P356
P1476
PPAR agonist-mediated protecti ...... anced in MMP-9-deficient mice.
@en
P2093
Michal Toborek
Minseon Park
P2860
P304
P356
10.1038/JCBFM.2013.240
P577
2014-01-15T00:00:00Z